Sandro R. P. da Rocha, Ph.D.
Associate Professor, Department of Chemical and Life Sciences Engineering VCU College of Engineering
- Richmond VA
Dr. da Rocha specializes in chemical engineering, biomedical engineering and nanotechnology.
Media
Social
Industry Expertise
Areas of Expertise
Education
University of Texas at Austin
Postdoc
Chemistry & Biochemistry
University of Texas at Austin
Ph.D.
Chemical Engineering
Federal University of Santa Catarina (Brazil)
M.S.
Chemical Engineering
Federal University of Santa Maria (Brazil)
B.S.
Chemical Engineering
Affiliations
- Frontiers in Colloidal Materials and Interfaces
- Journal of Pharmaceutics
- Advances in Pharmaceutics
- Chemical Engineering and Process Techniques
Media Appearances
VCU launches Center for Pharmaceutical Engineering and Sciences
Virginia Business online
2019-04-16
“The idea is to translate this new knowledge and discoveries into real products,” says Sandro R.P. da Rocha, a professor in the School of Pharmacy.
Selected Articles
Poly(amidoamine) Dendrimer–Doxorubicin Conjugates: In Vitro Characteristics and Pseudosolution Formulation in Pressurized Metered-Dose Inhalers
Molecular Pharmaceutics2016
Lung cancers are the leading cause of cancer death for both men and women. A series of PEGylated poly(amidoamine) dendrimer-based doxorubicin (DOX) nanocarriers (G3NH2-mPEG-nDOX) were synthesized and their chemistry tailored for the development of novel pseudosolution formulations in propellant-based metered-dose inhalers (pMDIs) with enhanced aerosol characteristics.
Effect of the Conjugation Density of Triphenylphosphonium Cation on the Mitochondrial Targeting of Poly(amidoamine) Dendrimers
Molecular Pharmaceutics2015
Many clinically relevant diseases with known poor therapeutic outcomes, including cancer and neurodegenerative disorders, have been directly linked to mitochondrial dysfunction. The ability to efficiently target therapeutics to intracellular organelles such as mitochondria may represent new opportunities for the effective treatment of such ailments.
Poly(amidoamine) Dendrimer Nanocarriers and Their Aerosol Formulations for siRNA Delivery to the Lung Epithelium
Molecular Pharmaceutics2014
Small interfering RNA (siRNA)-based therapies have great promise in the treatment of a number of prevalent pulmonary disorders including lung cancer, asthma and cystic fibrosis. However, progress in this area has been hindered due to the lack of carriers that can efficiently deliver siRNA to lung epithelial cells, and also due to challenges in developing oral inhalation (OI) formulations for the regional administration of siRNA and their carriers to the lungs.
